Original Article P1-hepatocyte nuclear factor 4α expression significantly correlates with the severity of chronic gastritis

Zhuxue Zhang^{1*}, Mingliang Chu^{1*}, Jianjun Hu¹, Wei Yi¹, Bowen Wang², Xiaobo Ma³

¹Department of Pathology, Guizhou Provincial People's Hospital, The Affiliated People's Hospital of Guizhou Medical University, Guiyang, China; ²Department of Surgery, Wisconsin Institute for Medical Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; ³Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. *Equal contributors.

Received March 6, 2017; Accepted May 3, 2017; Epub June 1, 2017; Published June 15, 2017

Abstract: To evaluate the expression pattern of hepatocyte nuclear factor 4α (HNF4 α) in chronic gastritis and reveal the relationship between HNF4 α expression and severity of chronic gastritis. Biopsy samples from the gastric mucosa of 225 patients and 5 control subjects were collected. The expressions of P1 promoter-driven HNF4 α (P1-HNF4 α) and P2 promoter-driven HNF4 α (P2-HNF4 α) in chronic gastritis were analyzed by immunohistochemical staining. Significant differences in P1-HNF4 α expression levels were observed between the different severity of chronic gastritis groups without intestinal metaplasia (IM) (P<0.05), while there was no difference in IM area for the P1-HNF4 α expression was widespread. The P2-HNF4 α strongly expressed in any gastric tissues, including normal epithelia, gastritis with various degrees of severity, and gastric IM. High level expression of P1-HNF4 α was associated with the severity of chronic gastritis. The P1-HNF4 α could be potentially useful as a diagnostic marker for chronic gastritis.

Keywords: HNF4 α , chronic gastritis, intestinal metaplasia

Introduction

Chronic gastritis, a common disease in human beings, is considered to be a multistep, progressive and lifelong inflammation [1]. Relevant factors of chronic gastritis were identified, including chemicals, immunologic, genetic activities and pathogenic bacteria [2]. Helicobacter pylori (H. pylori), which usually colonizes near the pyloric antrum, has been implicated as a principal cause of chronic gastritis [1, 3]. As a result of long-lasting reaction directed against H. pylori, gene expression would be shifts in the human gastric antrum, and a cascade of intestinal metaplasia (IM) events could occur [4].

Hepatocyte nuclear factor 4α (HNF4 α), which is one of the key regulators of hepatocyte differentiation in mammals, is implicated in the differentiation of the gastrointestinal tract during embryogenesis [5]. Several isoforms of HNF4 α have been cloned and characterized which result from alternative promoter (P1 and P2) usage and splicing [6, 7]. The distribution pattern of P1 and P2 promoter-driven HNF4 α differs among digestive tract organs: P1-HNF4 α is expressed in intestinal tissue and gastric intestinal metaplasia, while P2-HNF4 α is expressed in gastrointestinal tract [6-9].

Although numerous reports have shown that the expression patterns of isoforms P1 and P2-HNF4 α in gastrointestinal tract and pathologically changed tissues are different [6-10], the exact correlations between the expression patterns of various HNF4 α isoforms and the severity of inflammation in chronic gastritis have yet to be well defined. The aim of this study was to investigate the associations between the expression of P1-HNF4 α or P2-HNF4 α and the degree of inflammation in the pyloric mucosa.

Materials and methods

Tissue samples

225 patients (age 55.7±12.4 years) with functional dyspepsia admitted to endoscopy at

chronic inflammation in gastritis samples								
Chronic		0		Acti	Dualua			
in	inflammation	Case	0+	1+	2+	3+	P-value	
Μ	ild	65	38	21	6	0		
Μ	oderate	101	30	39	21	11		
Se	evere	59	0	10	26	23	P<0.05	

 Table 1. Correlation between activity and chronic inflammation in gastritis samples

Table 2. Correlation between activity andintestinal metaplasia in gastric mucosasamples

Chronic	Case -	IM*				Dualua
inflammation		0+	1+	2+	3+	P-value
Mild	65	41	17	7	0	
Moderate	101	53	23	19	6	
Severe	59	28	7	10	14	P<0.05

*IM: Intestinal metaplasia.

Guizhou Provincial People's Hospital were included in the study.

All patients were positive for H. pylori infection based on the positive results of the histology and/or C14 urea breath test. Patients were excluded if they had any of the following: gastrointestinal hemorrhage, atrophy, malignancy, immunosuppression, severe concomitant diseases, and use of any antibiotics or protonpump inhibitors in the 4 weeks prior to the study. Normal pylorus tissues were obtained from patients undergoing duodenal switch gastric bypass surgery. This study was approved by the ethics committee of Guizhou provincial people's hospital. Informed consent is obtained from each research subject before that subject participates in the research study.

Immunohistochemistry

Biopsy specimens were fixed in 10% formalin, embedded in paraffin and stained with Hematoxylin-Eosin. Immunostaining was performed using the Leica Bond-Max automation system (Leica Biosystems, Bannockburn, IL). Primary antibody Muc-2 (1:200; ZSGB-BIO, Beijing, China) was used to identify the presence of IM. Positive staining was localized to cytoplasm. Primary antibodies P1-HNF4 α (K9218, 1:500; R&D Systems, Minneapolis, MN) and P2-HNF4 α (H6939, 1:500; R&D Systems, Minneapolis, MN) were used to investigate the expression pattern in gastric epithelial cells. Nuclear staining was considered a positive reaction. The extent of HNF4 α expression in the area of gastric epithelium was graded semi-quantitatively as follows: 0+, no; 1+, extended to 1/10; 2+, from 1/10 to 5/10; 3+, more than 5/10 of the area. The assessment was made by a single senior pathologist (Z.Z).

Statistical analysis

The chi-square test was used to verify a significant association between activity, chronic inflammation, intestinal metaplasia, and P1-HNF4 α protein expression. Data were analyzed using statistical software (SPSS,version 13.0; SPSS Inc., Chicago, IL). A value of *P*<0.05 was considered as statistically significant.


Results

Inflammation activity and intestinal metaplasia in chronic gastritis

According to the updated Sydney System grading [11], 65 mild chronic gastritis, 101 moderate chronic gastritis and 59 severe chronic gastritis were included in the study. Meanwhile, 5 normal pylorus tissues were used as controls. Chronic gastritis is often accompanied by the activity. The findings showed a high grade of activity in severe chronic gastritis, and it was strongly correlated to the severity of chronic gastritis (Table 1, P<0.05). IM status was characterized by the appearance of goblet cells and expression of Muc-2. IM was not detected in any of 5 normal tissues, while IM was present in 24 mild inflammation samples (24/65, 36.9%), 48 moderate inflammation samples (48/101, 47.5%) and 31 severe inflammation samples (31/59, 52.5%). The frequency of IM was significantly associated with the severity of inflammation in chronic gastritis samples (Table 2, P<0.05).

$HNF4\alpha$ expression in chronic gastritis without intestinal metaplasia

P1-HNF4 α expression was not detectable in normal pylorus epithelia, while the inflamed epithelia had various expression levels of P1-HNF4 α in gastritis samples without IM (**Figure 1**). Among the 41 mild inflammation without IM cases, P1-HNF4 α expression was detectable in 8/41 cases (19.5%) (**Table 3**). In H & E



P1- HNF4a (K9218) P2- HNF4a (H6939)

Figure 1. P1-HNF4 α and P2-HNF4 α expression in gastric antral tissues. Chronic antral gastritis was categorized into mild, moderate and severe. Gastric antral epithelial cases were stained with hematoxylin and eosin (H&E) and immunohistochemistry of P1-HNF4 α and P2-HNF4 α . (Magnification, 200×).

Table 3. Correlation between P1-HNF4 α protein expression and chronic inflammation in samples without intestinal metaplasia

Chronic inflammation	Case	P1-HNF4α expression				P-value
(without IM*)			1+			. 1 -value
Mild	41	33	7	1	0	
Moderate	53	15	18	12	8	
Severe	28	1	3	9	15	P<0.05

*IM: Intestinal metaplasia.

53 moderate inflammation without IM cases, the expression of P1-HNF4 α was 38/53 cases (71.7%) (**Table 3**). Other 28 severe inflammation without IM cases, P1-HNF4 α expression was found in nearly all the cases (27/28, 96.4%) (**Table 3**). The expression degrees of P1-HNF4 α was significantly associated with the severity of inflammation in chronic gastritis samples (P<0.05). However, there was no significant difference of P1-HNF4 α expression between active or inactive in mild, moderate or severe chronic gastritis (data not shown). Unsurprisingly, the expression degrees of P2-HNF4 α had no difference from normal to severe inflammation samples, which were almost strongly staining positive (**Figure 1**).

$HNF4\alpha$ expression in chronic gastritis with intestinal metaplasia

The proportion of IM was different in various level of chronic samples, but the expression of P1-HNF4 α was almost the same in IM area, no matter how far the severity of chronic inflammation. Almost all cells in IM region were strongly stained for P1-HNF4 α (Figure 2). As for P2-HNF4 α , the immunoreactivity was seen in nearly all gastric cells and IM cells. In addition, there was little expression difference between any inflammation samples and normal tissues for P2-HNF4 α (Figure 2).




Figure 2. Muc-2, P1-HNF4 α and P2-HNF4 α expression in chronic antral gastritis with intestinal metaplasia. Patient samples were categorized into mild, moderate and severe. Gastric antral epithelial cases were stained with hematoxylin and eosin (H&E) and immunohistochemistry of Muc-2, P1-HNF4 α and P2-HNF4 α . (Magnification, 200×).

Discussion

H. pylori infection is well known to be associated with chronic gastritis, intestinal metaplasia and carcinoma [12, 13]. After a long-lasting infection, a number of pathological changes were occurred from normal pathway of gastric differentiation to chronic inflammation, IM and carcinoma [12, 13]. During this process, there were vast changes in gene expression profiles [6, 7, 9, 14-19]. Our results demonstrated that P1-HNF4α was not expressed on normal gastric mucosa, but it was associated with the severity of inflammation in chronic gastritis samples (Figure 1; Table 3). Especially, all of the IM area were strongly stained with P1-HNF4 α , no matter how far the severity of inflammation (Figure 2). Previous work has shown that IM may develop from gastric epithelium that has undergone chronic inflammation, and our study also showed that IM is more likely to occur in severe inflammation samples (**Table 2**). All in all, our findings indicated that the expression patterns of P1-HNF4 α were in line with the pathological process from gastric mucosa to IM.

Infection with H. pylori is the most common cause of chronic active gastritis [20]. Our results showed most of the severe chronic gastritis were active, but most of the mild inflammation gastric biopsies were inactive. The activity was strongly associated with the severity of inflammation (**Table 1**). However, there is no significant difference between the activity and inactivity in the expression of P1-HNF4 α in the same grade chronic gastritis (data not shown). We deduced that the progressive shift of P1-HNF4 α expression might need a prolonged inflammation, and chronic was more

representative of long-term reaction than activity. Further studies are needed to clarify this point.

Interestingly, P2-HNF4 α was strongly expressed in varied gastric tissues, including normal gastric epithelia, gastritis with various degrees of severity, and gastric IM (**Figures 1**, **2**). It has been reported that P2-HNF4 α is widely expressed in gastrointestinal tract [6-10]. Our results were in line with the previous reports and showed the expression status of P2-HNF4 α in chronic gastritis.

In conclusion, this study showed a different expression patterns of P1-HNF4 α and P2-HNF4 α in chronic gastritis. An increased expression of P1-HNF4 α was associated with the severity of inflammation in chronic gastritis, and the expression come to a head in gastric IM, while P2-HNF4 α expression was widespread and there was no difference in all chronic gastritis. These results suggest that the expression of P1-HNF4 α but not P2-HNF4 α may be a useful diagnostic marker for chronic gastritis.

Acknowledgements

This work was supported by the National Natural Science Foundation of China, under Grant 81560088; Science and Technology Foundation of Guizhou Province, under Grant J[2015]2086; and Guizhou Province Science and Technology Agency-Guizhou Provincial People's Hospital Joint Fund, under Grant LH[2015]7108.

Disclosure of conflict of interest

None.

Address correspondence to: Mingliang Chu and Wei Yi, Department of Pathology, Guizhou Provincial People's Hospital, The Affiliated People's Hospital of Guizhou Medical University, 83 Zhongshan Road, Guiyang 550002, China. Tel: +86-851-85936118; Fax: +86-851-85936118; E-mail: chumingliang@ foxmail.com (MLC); yiwei6252@sina.com (WY)

References

- [1] Sipponen P and Maaroos HI. Chronic gastritis. Scand J Gastroenterol 2015; 50: 657-667.
- [2] Rahmani A, Moradkhani A, Ahmadi MRH, Heirdarlo AJ, Abangah G, Asadollahi K and

Sayehmiri K. Association between serum levels of high sensitive C-reactive protein and inflammation activity in chronic gastritis patients. Scand J Gastroenterol 2016; 51: 531-537.

- Kusters JG, van Vliet AH and Kuipers EJ.
 Pathogenesis of helicobacter pylori infection.
 Clin Microbiol Rev 2006; 19: 449-490.
- [4] Goldenring JR and Nam KT. Oxyntic atrophy, metaplasia and gastric cancer. Prog Mol Biol Transl Sci 2010; 96: 117-131.
- [5] Duncan SA, Manova K, Chen WS, Hoodless P, Weinstein DC, Bachvarova RF and Darnell JE Jr. Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm in the implanting blastocyst. Proc Natl Acad Sci U S A 1994; 91: 7598-7602.
- [6] Takano K, Hasegawa G, Jiang S, Kurosaki I, Hatakeyama K, Iwanari H, Tanaka T, Hamakubo T, Kodama T and Naito M. Immunohistochemical staining for P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha may complement mucin phenotype of differentiated-type early gastric carcinoma. Pathol Int 2009; 59: 462-470.
- [7] Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, Daigo K, Ohashi R, Sugai M and Ikegame C. Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4α in the pathogenesis of human cancer. J Pathol 2006; 208: 662-672.
- [8] Jiang S, Tanaka T, Iwanari H, Hotta H, Yamashita H, Kumakura J, Watanabe Y, Uchiyama Y, Aburatani H and Hamakubo T. Expression and localization of P1 promoterdriven hepatocyte nuclear factor-4α (HNF4α) isoforms in human and rats. Nucl Recept 2003; 1: 5.
- [9] Kojima K, Kishimoto T, Nagai Y, Tanizawa T, Nakatani Y, Miyazaki M and Ishikura H. The expression of hepatocyte nuclear factor-4alpha, a developmental regulator of visceral endoderm, correlates with the intestinal phenotype of gastric adenocarcinomas. Pathology 2006; 38: 548-554.
- [10] Saandi T, Baraille F, Derbal-Wolfrom L, Cattin AL, Benahmed F, Martin E, Cardot P, Duclos B, Ribeiro A and Freund JN. Regulation of the tumor suppressor homeogene Cdx2 by HNF4 α in intestinal cancer. Oncogene 2012; 32: 3782-3788.
- [11] Dixon MF, Genta RM, Yardley JH and Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, houston 1994. Am J Surg Pathol 1996; 20: 1161-1181.

- [12] Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ 2004; 157: 301-310.
- [13] Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, Miwa H, Lim KJ and Das KM. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol 2014; 20: 5461-5473.
- [14] Busuttil R and Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol 2009; 24: 193-201.
- [15] Kim BW, Kim KM, Lee BI, Maeng LS, Choi H, Cho SH, Chae HS, Kim JK, Choi KY and Chung IS. Expression of trefoil peptides in the subtypes of intestinal metaplasia. Peptides 2004; 25: 779-783.
- [16] Song JY, Kim BW, Lee AW, Lee KY, Chung IS, Lee BI, Choi H, Ji JS, Chae HS, Choi KY. Expression of MUC5AC and trefoil peptide 1 (TFF1) in the subtypes of intestinal metaplasia. Clin Endosc 2012; 45: 151-154.

- [17] Tsukamoto T, Mizoshita T, Mihara M, Tanaka H, Takenaka Y, Yamamura Y, Nakamura S, Ushijima T and Tatematsu M. Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathology 2005; 46: 649-658.
- [18] Wang L, Zhang XY, Xu L, Liu WJ, Zhang J and Zhang JP. Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma. Oncol Lett 2011; 2: 707-712.
- [19] Zhang Y, Wang H, Bi C, Xiao Y and Liu Z. Expression of CDX2 in gastriccardia adenocarcinoma and its correlation with H. pylori and cell proliferation. Oncotarget 2016; 7: 54973-54982.
- [20] Rugge M and Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005; 36: 228-233.